Curis (NASDAQ:CRIS – Get Free Report) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.94) by ($0.11), RTT News reports. Curis had a negative net margin of 473.04% and a negative return on equity of 169.22%. During the same period in the prior year, the business earned ($2.40) EPS.
Curis Stock Up 0.2 %
Shares of CRIS opened at $16.20 on Wednesday. The business’s 50-day moving average price is $12.94 and its 200-day moving average price is $11.00. Curis has a twelve month low of $3.80 and a twelve month high of $19.60. The stock has a market cap of $95.48 million, a PE ratio of -1.81 and a beta of 3.59.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and issued a $26.00 price objective on shares of Curis in a research note on Wednesday.
Curis Company Profile
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Further Reading
- Five stocks we like better than Curis
- Investing in Commodities: What Are They? How to Invest in Them
- Celsius Stock’s Post-Earnings Morning Dip, Better than Coffee
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Chegg Chokes on AI Attempt, CEO Talks it Up As He Passes Torch
- Pros And Cons Of Monthly Dividend Stocks
- Does Logitech’s EPS Beat Signal the Rebound of Video Gaming?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
